PubMed: Multi targets of cannabidiol (CBD) on skeletal mammalian and avian neuromuscular preparations

PubMed: Multi targets of cannabidiol (CBD) on skeletal mammalian and avian neuromuscular preparations

Nat Prod Res. 2023 Dec 6:1-10. doi: 10.1080/14786419.2023.2290675. Online ahead of print.

ABSTRACT

Cannabidiol (CBD) has been used in diseases that affect the central nervous system. Its effects on the peripheral synapses are of great interest, since endocannabinoid receptors are expressed in muscles. CBD (0.3 mM) was analysed using mammalian and avian neuromuscular preparations, through myographic techniques in complementary protocols. Mammalian cells were examined by light microscopy while exogenous acetylcholine (40 µM) and potassium chloride (100 mM) were added into avian preparations, before and at the end of experiments. Pharmacological tools such as atropine (2 µM), polyethylene glycol (PEG 400, 20 µM), Ca2+ (1.8 mM), F55-6 (20 µg/mL), and nifedipine (1.3 mM) were assessed with CBD. In mice, CBD causes a facilitatory effect and paralysis, whereas in avian, paralysis. Concluding, CBD is responsible for activated or inhibited channels, for ACh release via muscarinic receptor modulation, and by the inhibition of nicotinic receptors leading to neuromuscular blockade, with no damage to striated muscle cells.

PMID:38054804 | DOI:10.1080/14786419.2023.2290675

https://pubmed.ncbi.nlm.nih.gov/38054804/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Ds1JEbG0OWaBdqM3tTUGjkFhFGaOtMecPdpuvzbuubWi6d9Fn&fc=20231022105433&ff=20231206132140&v=2.17.9.post6+86293ac December 6, 2023 11:00 am